[go: up one dir, main page]

MA28901B1 - Methode de traitement de cancers - Google Patents

Methode de traitement de cancers

Info

Publication number
MA28901B1
MA28901B1 MA29554A MA29554A MA28901B1 MA 28901 B1 MA28901 B1 MA 28901B1 MA 29554 A MA29554 A MA 29554A MA 29554 A MA29554 A MA 29554A MA 28901 B1 MA28901 B1 MA 28901B1
Authority
MA
Morocco
Prior art keywords
treating cancers
cancers
treating
Prior art date
Application number
MA29554A
Other languages
English (en)
Inventor
Mark S Berger
Tona Morgan Gilmer
Arundathy Nirmalini Pandite
Original Assignee
Smithkline Beecham Cork Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Cork Ltd filed Critical Smithkline Beecham Cork Ltd
Publication of MA28901B1 publication Critical patent/MA28901B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pulmonology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MA29554A 2004-06-04 2006-12-25 Methode de traitement de cancers MA28901B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US57733704P 2004-06-04 2004-06-04

Publications (1)

Publication Number Publication Date
MA28901B1 true MA28901B1 (fr) 2007-10-01

Family

ID=35503649

Family Applications (1)

Application Number Title Priority Date Filing Date
MA29554A MA28901B1 (fr) 2004-06-04 2006-12-25 Methode de traitement de cancers

Country Status (14)

Country Link
US (1) US20090317383A1 (fr)
EP (1) EP1765344A4 (fr)
JP (1) JP2008501708A (fr)
KR (1) KR20070034536A (fr)
CN (2) CN101564535A (fr)
AU (2) AU2005251769B2 (fr)
BR (1) BRPI0511765A (fr)
CA (1) CA2569139A1 (fr)
IL (1) IL179323A0 (fr)
MA (1) MA28901B1 (fr)
MX (1) MXPA06013952A (fr)
NO (1) NO20066079L (fr)
RU (2) RU2361589C2 (fr)
WO (1) WO2005120512A2 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006066267A2 (fr) * 2004-12-17 2006-06-22 Smithkline Beecham (Cork) Limited Technique de traitement de cancer
WO2007143483A2 (fr) * 2006-06-01 2007-12-13 Smithkline Beecham Corporation Procédé de traitement du cancer
JP2010501572A (ja) * 2006-08-22 2010-01-21 コンサート ファーマシューティカルズ インコーポレイテッド ４−アミノキナゾリン誘導体およびその使用方法
AU2007307489A1 (en) 2006-10-06 2008-04-17 Takeda Pharmaceutical Company Limited Combination drug
EP2088862A4 (fr) * 2006-11-28 2009-12-02 Smithkline Beecham Cork Ltd Méthode de traitement du cancer
EP2126117A2 (fr) * 2007-01-18 2009-12-02 University Of Southern California Polymorphismes géniques prédictifs d'une bithérapie à base de tki
PE20091624A1 (es) 2008-03-03 2009-11-19 Takeda Pharmaceutical Farmaco combinado a base de un inhibidor de her2 derivado de pirrolopirimidina o pirazolopirimidina
WO2009137714A2 (fr) 2008-05-07 2009-11-12 Teva Pharmaceutical Industries Ltd. Formes de ditosylate de lapatinib et procédés pour leur préparation
CN104523661A (zh) 2009-02-06 2015-04-22 南加利福尼亚大学 含有单萜的治疗组合物
US8568968B2 (en) 2009-04-13 2013-10-29 University Of Southern California EGFR polymorphisms predict gender-related treatment
US20140302050A1 (en) * 2011-11-09 2014-10-09 Albert Einstein College Of Medicine Of Yeshiva University Targeting an amphiregulin-derived cell surface neo-epitope

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5786344A (en) * 1994-07-05 1998-07-28 Arch Development Corporation Camptothecin drug combinations and methods with reduced side effects
DK0994706T3 (da) * 1997-05-27 2006-03-06 Ivax Research Inc Præparater til oral indgivelse af taxaner og anvendelse deraf
GB9800569D0 (en) * 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
EE200200471A (et) * 2000-02-28 2003-12-15 Aventis Pharma S.A. Farmatseutiline kompositsioon, mis sisaldab kamptotetsiini või selle derivaati kombinatsioonis pürimidiini derivaadiga ning on ette nähtud vähktõve raviks
NZ522989A (en) * 2000-06-30 2005-06-24 Glaxo Group Ltd Quinazoline ditosylate salt compounds
EP1353693B1 (fr) * 2001-01-16 2005-03-16 Glaxo Group Limited Combinaison pharmaceutique contenant de l'amino-4 quinazoline et paclitaxel, carboplatin or vinorelbine pour le traitement du cancer
PA8578001A1 (es) * 2002-08-07 2004-05-07 Warner Lambert Co Combinaciones terapeuticas de inhibidores de quinasa de erb b y terapias antineoplasicas
EP1653986A4 (fr) * 2003-08-01 2007-03-14 Smithkline Beecham Corp Traitement des cancers exprimant p95 sp erbb2 /sp
US8211030B2 (en) * 2009-03-26 2012-07-03 The General Electric Company NIBP target inflation pressure automation using derived SPO2 signals

Also Published As

Publication number Publication date
EP1765344A2 (fr) 2007-03-28
CA2569139A1 (fr) 2005-12-22
CN1984656A (zh) 2007-06-20
AU2005251769B2 (en) 2008-10-02
NO20066079L (no) 2007-01-12
BRPI0511765A (pt) 2008-01-08
WO2005120512A2 (fr) 2005-12-22
RU2008150250A (ru) 2010-06-27
RU2006142418A (ru) 2008-07-20
WO2005120512A3 (fr) 2006-04-27
JP2008501708A (ja) 2008-01-24
EP1765344A4 (fr) 2009-12-02
US20090317383A1 (en) 2009-12-24
CN101564535A (zh) 2009-10-28
IL179323A0 (en) 2007-05-15
KR20070034536A (ko) 2007-03-28
RU2361589C2 (ru) 2009-07-20
AU2005251769A1 (en) 2005-12-22
AU2008229859A1 (en) 2008-10-30
MXPA06013952A (es) 2007-02-08
CN1984656B (zh) 2010-05-26

Similar Documents

Publication Publication Date Title
FR21C1063I1 (fr) Traitement combiné de tumeurs exprimant la cd38
EP1732650A4 (fr) Composition et methode de traitement du cancer
EP1667680A4 (fr) Methodes combinees de traitement du cancer
EP1575580A4 (fr) Methodes de traitement de cancers
EP1830876A4 (fr) Traitement de metastases cutanees
EP1636359A4 (fr) Methodes de traitement de la douleur
EP1755584A4 (fr) Traitement de la myopie
EP1991230A4 (fr) Méthodes de traitement du cancer
EP1830869A4 (fr) Procede de traitement ou prophylaxie
DK1706112T3 (da) Fremgangsmåder til at behandle en inflammatorisk-beslægtet sygdom
EP1968582A4 (fr) Traitement du lymphome t cutane
EP1982660A4 (fr) Endoscope de traitement
DE602005012489D1 (de) Verfahren zur Abwasserbehandlung
EP1677816A4 (fr) Methode de traitement
EP1680073A4 (fr) Composes et methode de traitement du cancer
BRPI0810206A2 (pt) Método de tratar câncer
CR9878A (es) Tratamiento y profilaxis de microangiopatias
EP1838714A4 (fr) Procedes de traitement de la douleur
EP1838330A4 (fr) Traitement de cancers solides
DE602005016127D1 (de) Substituierte hydantoine zur krebsbehandlung
MA28901B1 (fr) Methode de traitement de cancers
EP1833511A4 (fr) Methode de traitement du cancer du cerveau
EP1677805A4 (fr) Traitement du cancer du pancreas
EP1937892A4 (fr) Methode de traitement de materiaux lignocellulosiques
EP2219452A4 (fr) Procédés de traitement de la sclérodermie